These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 17105813)

  • 1. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
    Shaughnessy JD; Zhan F; Burington BE; Huang Y; Colla S; Hanamura I; Stewart JP; Kordsmeier B; Randolph C; Williams DR; Xiao Y; Xu H; Epstein J; Anaissie E; Krishna SG; Cottler-Fox M; Hollmig K; Mohiuddin A; Pineda-Roman M; Tricot G; van Rhee F; Sawyer J; Alsayed Y; Walker R; Zangari M; Crowley J; Barlogie B
    Blood; 2007 Mar; 109(6):2276-84. PubMed ID: 17105813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
    Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
    Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.
    Balcárková J; Urbánková H; Scudla V; Holzerová M; Bacovský J; Indrák K; Jarosová M
    Cancer Genet Cytogenet; 2009 Jul; 192(2):68-72. PubMed ID: 19596256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional features of multiple myeloma patients with chromosome 1q gain.
    Fabris S; Ronchetti D; Agnelli L; Baldini L; Morabito F; Bicciato S; Basso D; Todoerti K; Lombardi L; Lambertenghi-Deliliers G; Neri A
    Leukemia; 2007 May; 21(5):1113-6. PubMed ID: 17315022
    [No Abstract]   [Full Text] [Related]  

  • 6. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
    Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
    Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
    Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
    Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
    Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
    [No Abstract]   [Full Text] [Related]  

  • 9. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.
    Kassambara A; Hose D; Moreaux J; Walker BA; Protopopov A; Reme T; Pellestor F; Pantesco V; Jauch A; Morgan G; Goldschmidt H; Klein B
    Haematologica; 2012 Apr; 97(4):622-30. PubMed ID: 22102711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 1 instability in multiple myeloma: Aberrant gene expression, pathogenesis, and potential therapeutic target.
    Luo S; Su T; Zhou X; Hu WX; Hu J
    FASEB J; 2022 Jun; 36(6):e22341. PubMed ID: 35579877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
    Shaughnessy J
    Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
    Mohan M; Weinhold N; Schinke C; Thanedrarajan S; Rasche L; Sawyer JR; Tian E; van Rhee F; Zangari M
    Br J Haematol; 2020 Apr; 189(1):67-71. PubMed ID: 31820442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.
    Krzeminski P; Corchete LA; García JL; López-Corral L; Fermiñán E; García EM; Martín AA; Hernández-Rivas JM; García-Sanz R; San Miguel JF; Gutiérrez NC
    Oncotarget; 2016 Dec; 7(49):80664-80679. PubMed ID: 27811368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
    Jenner MW; Leone PE; Walker BA; Ross FM; Johnson DC; Gonzalez D; Chiecchio L; Dachs Cabanas E; Dagrada GP; Nightingale M; Protheroe RK; Stockley D; Else M; Dickens NJ; Cross NC; Davies FE; Morgan GJ
    Blood; 2007 Nov; 110(9):3291-300. PubMed ID: 17609426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
    Johnson TS; Sudha P; Liu E; Becker N; Robertson S; Blaney P; Morgan G; Chopra VS; Dos Santos C; Nixon M; Huang K; Suvannasankha A; Zaid MA; Abonour R; Walker BA
    Nat Commun; 2024 May; 15(1):4144. PubMed ID: 38755140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma.
    Agnelli L; Bicciato S; Fabris S; Baldini L; Morabito F; Intini D; Verdelli D; Callegaro A; Bertoni F; Lambertenghi-Deliliers G; Lombardi L; Neri A
    Haematologica; 2007 Jan; 92(1):56-65. PubMed ID: 17229636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.
    Chng WJ; Gertz MA; Chung TH; Van Wier S; Keats JJ; Baker A; Bergsagel PL; Carpten J; Fonseca R
    Leukemia; 2010 Apr; 24(4):833-42. PubMed ID: 20220778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
    Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.